Urogen Pharma (NASDAQ: URGN) shares soared 9.7% in the last trading session to close at $19.20. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 32.5% gain over the past four weeks. Last week, the company announced data from the phase III ENVISION study evaluating UGN-102 as a potential non-surgical treatment for patients with low-grade intermediate-risk non-muscle invasive bladder cancer. Data from the study demonstrated an 82.3% 12-month duration of response by Kaplan-Meier estimate in patients who achieved complete response at three months following the first ...